Xenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock?
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.
Xenon Pharmaceuticals Inc. (XENE) Q1 2025 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 AM ET Corporate Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Conference Call Participants Paul Matteis - Stifel Tessa Romero - JPMorgan Brian Abrahams - RBC Capital Markets Brian Skorney - Baird Myles Minter - William Blair Dylan Shindler - Wedbush Daniel Ni - Goldman Sachs Andrew Tsai - Jefferies Joseph Thome - TD Cowen Operator Thank you for standing by. My name is Carly, and I will be your conference operator today.
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 48.2% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Xenon- A Later Stage Story
Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming phase III data expected by end of 2025. Azetukalner's unique Kv7 potassium channel mechanism and rapid onset of action could address unmet needs in treatment-resistant epilepsy and potentially depression. Financially stable, Xenon is well-funded into 2027, with potential $1Bn market opportunity if azetukalner succeeds in focal onset seizures and expands into other indications.
Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data
Xenon Pharmaceuticals Inc.'s lead asset, azetukalner (XEN1101), shows promising phase 2b results for focal onset seizures (FOS) and is in phase 3 trials for FOS and PGTCS. Despite failing to meet the primary endpoint in an MDD trial, azetukalner's potential in epilepsy remains strong, with long-term data showing sustained seizure reduction. Financially, Xenon Pharma has a solid cash position, providing a runway of 11–13 quarters, making it an attractive investment at current low prices.
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Conference Call Participants Paul Matteis - Stifel Caroline Poacher - JPMorgan Brian Skorney - Baird Jason Gerberry - Bank of America Sarah Schram - William Blair Laura Chico - Wedbush Securities Joseph Thome - TD Cowen Douglas Tsao - H.C. Wainwright Operator Hello and thank you for standing by.
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
Xenon Pharmaceuticals' Azetukalner has good Phase 2 data for MDD using Kv7 potassium channels. This also gives it a good safety profile. The company has robust financials with a runway that should last into 2027 or more. So, I think it should have enough resources to take its late-stage pipeline to approval. Epilepsy and MDD have an attractive TAM of several billions of dollars in the US and abroad. XENE could tap into these niche markets over time.
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue?
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock?
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Caroline Pocher - JPMorgan Andrew Tsai - Jefferies Brian Abrahams - RBC Capital Markets Luke Herrmann - Baird Jason Gerberry - Bank of America Sarah Schram - William Blair Paul Choi - Goldman Sachs Danielle Brill - Raymond James Marc Goodman - Leerink Partners Joseph Thome - TD Cowen Dylan Shindler - Wedbush Securities Operator Good afternoon, and thank you for standing by. At this time, I'd like to welcome everyone to Xenon Pharmaceuticals, Inc. Third Quarter 2024 Earnings Conference Call.
